The future of antiviral immunotoxins

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Leukocyte Biology

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1189/jlb.2MR1015-468RPMID 26729815
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

  2017cited by this paper
• Immunotoxin therapy for hematologic malignancies: where are we heading?

  2016cited by this paper
• Unexpected patterns of Epstein–Barr virus transcription revealed by a High throughput PCR array for absolute quantification of viral mRNA

  2015cited by this paper
• The Viral G Protein-Coupled Receptor ORF74 Hijacks β-Arrestins for Endocytic Trafficking in Response to Human Chemokines

  2015cited by this paper
• What Will It Take to Cure HIV?

  2015cited by this paper
• Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo

  2015influential reference
• EBV, the human host, and the 7TM receptors: defense or offense?

  2015cited by this paper
• Broad-spectrum antiviral agents

  2015cited by this paper
• Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART

  2014cited by this paper
• Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

  2014cited by this paper
• Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

  2014cited by this paper
• Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

  2014cited by this paper
• Antiviral Activity of a Single-Domain Antibody Immunotoxin Binding to Glycoprotein D of Herpes Simplex Virus 2

  2014cited by this paper
• Identification and Functional Comparison of Seven-Transmembrane G-Protein-Coupled BILF1 Receptors in Recently Discovered Nonhuman Primate Lymphocryptoviruses

  2014cited by this paper
• Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?

  2014cited by this paper
• The development of immunoconjugates for targeted cancer therapy

  2014cited by this paper
• Thirty years on: HIV receptor gymnastics and the prevention of infection

  2013cited by this paper
• Immunotoxins: The Role of the Toxin †

  2013cited by this paper
• Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

  2013cited by this paper
• Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

  2013cited by this paper
• B cell localization: regulation by EBI2 and its oxysterol ligand.

  2013cited by this paper
• Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

  2013cited by this paper
• Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

  2012cited by this paper
• A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Risks and untoward toxicities of antibody-based immunoconjugates.

  2012cited by this paper
• Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

  2012cited by this paper
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

  2012cited by this paper
• Prevention of Cellular Suicide by Cytomegaloviruses

  2012cited by this paper
• Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

  2012cited by this paper
• A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

  2011cited by this paper
• An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.

  2011cited by this paper
• Therapeutic potential of anticancer immunotoxins.

  2011cited by this paper
• Radioimmunotherapy of solid tumors: searching for the right target.

  2011cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• Thirty Years of HIV and AIDS: Future Challenges and Opportunities

  2011cited by this paper
• A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

  2011cited by this paper
• A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

  2011cited by this paper
• HSV-2: in pursuit of a vaccine.

  2011cited by this paper
• Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

  2010cited by this paper
• Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

  2010cited by this paper
• Cell transformation mediated by the Epstein–Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling

  2010cited by this paper
• Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

  2010cited by this paper
• Antiretroviral therapy and management of HIV infection.

  2010cited by this paper
• Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

  2010cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.

  2010cited by this paper
• Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

  2010cited by this paper
• A novel composite immunotoxin that suppresses rabies virus production by the infected cells.

  2010cited by this paper
• A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

  2009cited by this paper
• Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

  2009cited by this paper
• Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

  2009cited by this paper
• Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.

  2009cited by this paper
• Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.

  2008cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Efficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials

  2008cited by this paper
• A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

  2008cited by this paper
• An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.

  2008cited by this paper
• CONVECTION‐ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN‐13‐PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL SAFETY RESULTS

  2007cited by this paper
• Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

  2007cited by this paper
• Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

  2007cited by this paper
• Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system.

  2007cited by this paper
• Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

  2007cited by this paper
• Anti‐HIV‐1 immunotoxin 3B3(Fv)‐PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques

  2006cited by this paper
• Molecular Pharmacological Phenotyping of EBI2

  2006cited by this paper
• Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1

  2006cited by this paper
• How many drug targets are there?

  2006cited by this paper
• Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

  2005cited by this paper
• Virus-encoded chemokine receptors--putative novel antiviral drug targets.

  2005cited by this paper
• Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor

  2005cited by this paper
• A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.

  2005cited by this paper
• The Epstein-Barr Virus BILF1 Gene Encodes a G Protein-Coupled Receptor That Inhibits Phosphorylation of RNA-Dependent Protein Kinase

  2005cited by this paper
• The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections

  2005cited by this paper
• Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

  2005cited by this paper
• Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.

  2004cited by this paper
• Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1

  2004cited by this paper
• Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.

  2004cited by this paper
• HCMV-encoded chemokine receptor US28 employs multiple routes for internalization.

  2004cited by this paper
• Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis

  2003cited by this paper
• A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.

  2003cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Interleukin-4-Pseudomonas Exotoxin Chimeric Fusion Protein for Malignant Glioma Therapy

  2003cited by this paper
• cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

  2003cited by this paper
• Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas

  2003cited by this paper
• Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

  2003cited by this paper
• Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma

  2003cited by this paper
• Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

  2002cited by this paper
• Response 12: International Forum

  2002cited by this paper
• A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

  2002cited by this paper
• A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.

  2002cited by this paper
• Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

  2002cited by this paper
• Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.

  2002cited by this paper
• Endocytosis of the Viral Chemokine Receptor US28 Does Not Require Beta‐Arrestins But Is Dependent on the Clathrin‐Mediated Pathway

  2002cited by this paper
• A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer.

  2002cited by this paper
• Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

  2001cited by this paper
• Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

  2001cited by this paper
• Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

  2001cited by this paper
• The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling.

  2001cited by this paper
• Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.

  2001cited by this paper

• Design and Characterization of Ricin Based Immunotoxins Against EPHA2 Receptor for Breast Cancer Therapy: An In-Silico Study

  2025cites this paper
• Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

  2024cites this paper
• In vitro analysis of single chain variable fragment-based immunotoxins against Erythropoietin-producing hepatocellular A2 receptor overexpressed in breast cancer cells.

  2024cites this paper
• Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context

  2023cites this paper
• Methods to Produce Monoclonal Antibodies for the Prevention and Treatment of Viral Infections

  2022cites this paper
• Constitutive Signaling by the Human Cytomegalovirus G Protein Coupled Receptor Homologs US28 and UL33 Enables Trophoblast Migration In Vitro

  2022influential citation
• Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma

  2022cites this paper
• Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma.

  2022cites this paper
• Current innovative engineered antibodies.

  2022cites this paper
• Epstein-Barr Virus-Encoded BILF1 Orthologues From Porcine Lymphotropic Herpesviruses Display Common Molecular Functionality

  2022cites this paper
• Antiviral Activity of Ribosome-Inactivating Proteins

  2021cites this paper
• An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells

  2021cites this paper
• Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.

  2021cites this paper
• Engineered antibody fusion proteins for targeted disease therapy.

  2021cites this paper
• Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture

  2019cites this paper
• Immunotoxins: Targeted Toxin Delivery for Cancer Therapy

  2019cites this paper
• Application of therapeutic protein-based fusion toxins

  2019cites this paper
• An optimized aptamer-binding viral tegument protein VP8 inhibits the production of Bovine Herpesvirus-1 through blocking nucleocytoplasmic shuttling.

  2019cites this paper
• Antiviral Immunotoxin Against Bovine herpesvirus-1: Targeted Inhibition of Viral Replication and Apoptosis of Infected Cell

  2018influential citation
• Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases

  2018cites this paper
• Bovine single chain Fv antibody inhibits bovine herpesvirus-1 infectivity by targeting viral glycoprotein D

  2017cites this paper
• Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells

  2017cites this paper
• Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope

  2017cites this paper
• Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein

  2017cites this paper
• A new age for biomedical applications of Ribosome Inactivating Proteins (RIPs): from bioconjugate to nanoconstructs

  2016cites this paper